On 2026-06-05, the label for tofacitinib (Xeljanz, Xeljanz XR) was updated by the FDA to include a comprehensive boxed warning. This significant revision highlights that patients treated with tofacitinib tablets are at increased risk for developing serious infections, including bacterial, fungal, and viral types. The warning also addresses concerns regarding mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis.
Background
Tofacitinib, known by its brand names Xeljanz and Xeljanz XR, is a medication that has undergone a label revision. This update specifically pertains to the safety information for patients receiving tofacitinib citrate tablets, emphasizing critical risks associated with its use.
What this means
The implementation of a boxed warning on the tofacitinib label on 2026-06-05 represents a significant update to its safety profile. This warning informs healthcare professionals and patients about several serious potential risks associated with the drug. Specifically, it highlights an increased risk for serious infections, which can include bacterial, fungal, and viral infections. Furthermore, the warning addresses concerns regarding mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis. For clinicians, this means a heightened need for careful patient selection, thorough risk assessment, and vigilant monitoring for any signs of these adverse events throughout the course of treatment. The warning underscores the importance of weighing the potential benefits of tofacitinib against these serious risks, particularly in vulnerable patient populations. Patient advocates can use this information to ensure individuals are fully informed about the potential side effects and to facilitate discussions with their healthcare providers about treatment options and safety protocols.
Source
This label revision was issued by the FDA, effective 2026-06-05. The information is available on the DailyMed website, hosted by dailymed.nlm.nih.gov.